Human TrkA / NTRK1 Protein (aa 194-413, His Tag)
MTC,p140-TrkA,TRK,Trk-A,TRK1,TRKA
- 100ug (NPP4349) Please inquiry
| Catalog Number | P11073-H07H2 |
|---|---|
| Organism Species | Human |
| Host | Human Cells |
| Synonyms | MTC,p140-TrkA,TRK,Trk-A,TRK1,TRKA |
| Molecular Weight | The recombinant human NTRK1 Ig-like C2-type 1 & 2 domains (aa 194-413) consists of 239 amino acids and has a predicted molecular mass of 26 kDa. As a result of glycosylation, it migrates as an approximately 45-50 kDa band in SDS-PAGE under reducing conditions. |
| predicted N | His |
| SDS-PAGE |  |
| Purity | > 95 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the amino acid sequence (Pro 194-Glu 413) of human NTRK1 (NP_002520.2), corresponding to the Ig-like C2-type 1 & 2 domains, was expressed and purified, with a N-terminal polyhistidine tag. |
| Bio-activity | Measured by its ability to inhibit NGF-induced proliferation of TF1 human erythroleukemic cells. The ED50 for this effect is typically 0.5-4 μg/ml in the presence of 10 ng/mL of human NGF. |
| Research Area | Cancer |Signal transduction |Receptor Tyrosine Kinases (RTKs) |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma. |
| Reference |